<DOC>
	<DOC>NCT00650026</DOC>
	<brief_summary>Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Rheumatoid Arthritis</brief_summary>
	<brief_title>Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Eighteen years or older Females postmenopausal for at least 1 year, surgically sterile or practicing an acceptable method of birth control Females negative pregnancy test at screening Confirmed diagnosis of active RA &gt;= 6 swollen joints and &gt;= 9 tender joints Met ACR criteria for diagnosis of RA for at least 3 months Active RA defined by a DAS &gt;= 3.2 at study entry Subject had prior treatment with cyclophosphamide or chlorambucil Subjects previously treated with total lymphoid irradiation or antiCD4 or CAMPATH 1H monoclonal antibodies resulting in CD4 lymphopenia Prior treatment with intravenous immunoglobulin or investigational agent in with 30 days or 5 halflives of adalimumab Subject with history of cancer within the past 10 years other than resected basal cell or squamous cell carcinoma of the skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>